Security
Aldeyra Therapeutics, Inc. Common Stock · ALDX
ALDXNASDAQCommon stockCurrentCIK 1341235Updated Nov 18, 2026
ALDX price & chart
Loading TradingView…
NASDAQ:ALDX on TradingView ↗About the company
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248 and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma.
In the news
Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX ↗
Seeking Alpha
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow ↗
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript ↗
Aldeyra Therapeutics to appeal FDA rejection of dry eye disease drug reproxalap ↗
Recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
4 filing
4 filing
SCHEDULE 13G/A - filed by AQR CAPITAL MANAGEMENT LLC regarding Aldeyra Therapeutics, Inc.
Other Events
Items 8.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 77,801,012Source | 117,319,352Source | 47,540,559Source | 84,962,888Source | 126,043,834Source | 66,483,081Source | 93,195,717Source | 141,301,892Source | 72,059,317Source | 104,606,694Source | 148,326,911Source | 181,291,657Source |
| Property, Plant and Equipment, NetUSD | — | 1,360Source | 20,544Source | — | 2,720Source | — | — | 4,079Source | — | 0Source | 5,764Source | 19,279Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 59,340,599Source | 68,120,029Source | — | 41,241,269Source | 71,029,723Source | — | 50,350,617Source | 102,491,900Source | 70,041,254Source | 54,527,092Source | — | 144,419,364Source |
| Assets, CurrentUSD | 77,460,035Source | 116,720,763Source | 47,378,906Source | 84,558,228Source | 125,649,519Source | 66,273,819Source | 92,728,775Source | 140,845,946Source | 71,783,456Source | 104,072,478Source | 147,810,333Source | 181,023,113Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,162,696Source | 3,976,564Source | 2,289,120Source | 2,638,589Source | 5,317,836Source | 1,271,514Source | 2,670,698Source | 7,808,596Source | 1,742,202Source | 2,921,206Source | 4,987,317Source | 6,722,229Source |
| Operating Lease, Right-of-Use AssetUSD | 340,977Source | 329,968Source | 141,109Source | 404,660Source | 391,595Source | 209,262Source | 466,942Source | 451,867Source | 275,861Source | 266,955Source | 510,814Source | 249,265Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 28,556,469Source | 32,223,648Source | 9,655,256Source | 29,674,746Source | 27,733,495Source | 24,326,289Source | 29,597,140Source | 27,882,451Source | 27,808,927Source | 33,601,823Source | 28,531,881Source | 30,283,628Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 60,163Source | 59,550Source | 60,321Source | 60,046Source | 59,415Source | 60,321Source | 60,046Source | 59,415Source | 60,163Source | 59,648Source | 59,196Source | 58,560Source |
| Retained Earnings (Accumulated Deficit)USD | -477,495,746Source | -434,301,825Source | -492,860,145Source | -469,807,405Source | -419,188,842Source | -487,409,872Source | -460,040,093Source | -402,341,270Source | -483,957,253Source | -450,110,592Source | -394,259,148Source | -356,716,638Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 815Source | 66,540Source | — | -10,995Source | -9,658Source | — | 1,598Source | -3,029Source | 0Source | 37,442Source | 0Source | -103,938Source |
| Stockholders' Equity Attributable to ParentUSD | 49,244,543Source | 85,095,704Source | 37,885,303Source | 55,288,142Source | 98,310,339Source | 42,156,792Source | 63,598,577Source | 113,419,441Source | 44,250,390Source | 71,004,871Source | 119,795,030Source | 151,008,029Source |
| Additional Paid in Capital, Common StockUSD | 526,679,311Source | 519,271,439Source | 530,685,127Source | 525,046,496Source | 517,449,424Source | 529,506,343Source | 523,577,026Source | 515,704,325Source | 528,147,480Source | 521,018,373Source | 513,994,982Source | 507,770,045Source |
| Liabilities and EquityUSD | 77,801,012Source | 117,319,352Source | 47,540,559Source | 84,962,888Source | 126,043,834Source | 66,483,081Source | 93,195,717Source | 141,301,892Source | 72,059,317Source | 104,606,694Source | 148,326,911Source | 181,291,657Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 28,483,933Source | 17,153,414Source | 9,655,256Source | 29,531,299Source | 27,594,602Source | 24,326,289Source | 14,285,842Source | 21,676,437Source | 27,808,927Source | 18,601,823Source | 22,260,250Source | 15,360,538Source |
| Operating Lease, Liability, CurrentUSD | 271,948Source | 263,241Source | 143,447Source | 263,551Source | 255,039Source | 212,769Source | 255,342Source | 247,021Source | 280,537Source | 271,631Source | 239,183Source | 249,265Source |
| Accounts Payable, CurrentUSD | 13,423Source | 186,919Source | 137,476Source | 1,455,271Source | 254,434Source | 141,356Source | 346,146Source | 280,299Source | 158,461Source | 180,453Source | 1,338,057Source | 133,625Source |
| Operating Lease, Liability, NoncurrentUSD | 72,536Source | 70,234Source | 0Source | 143,447Source | 138,893Source | 0Source | 212,769Source | 206,014Source | 0Source | 0Source | 271,631Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 6,999,297Source | 10,423,297Source | 3,374,333Source | 6,663,580Source | 5,842,802Source | 2,672,164Source | 7,684,354Source | 5,944,419Source | 6,120,297Source | 12,118,367Source | 5,536,464Source | 14,065,885Source |
| Deferred Revenue, CurrentUSD | — | 6,000,000Source | — | — | 6,000,000Source | — | — | — | 6,000,000Source | 6,000,000Source | — | — |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Long-term Debt, Current MaturitiesUSD | 15,199,265Source | 279,957Source | 0Source | 15,148,897Source | 15,242,327Source | 15,300,000Source | 0Source | 15,204,698Source | 15,249,632Source | 31,372Source | 15,146,546Source | 911,763Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 15,000,000Source | — | 0Source | 0Source | 0Source | 15,098,529Source | 0Source | 0Source | 15,000,000Source | 0Source | 14,923,090Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -3,452,619Source | -9,929,501Source | -33,846,661Source | -55,851,444Source | -37,542,510Source | -62,024,636Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | -987,554Source | 2,224,013Source | 6,091,413Source | 7,973,499Source | 5,752,771Source | 8,288,976Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -17,105Source | 165,693Source | -21,992Source | -1,157,604Source | 1,204,432Source | -886,077Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,110,089Source | -12,469,699Source | -33,345,682Source | -43,208,747Source | -30,326,128Source | -56,637,187Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 7,290,414Source | 47,736,288Source | -44,915,755Source | 30,000,000Source | -29,954,530Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 16,317Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | 0Source | 532,951Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 71,140Source | 1,002,810Source | 1,123,556Source | -171,422Source | -1,270,220Source | 1,220,092Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -5,038,949Source | -4,176,475Source | 15,514,162Source | -88,295,924Source | -1,596,348Source | -85,371,625Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 59,340,599Source | 68,120,029Source | 45,089,786Source | 41,241,269Source | 65,002,305Source | 50,350,617Source | 70,041,254Source | 54,527,092Source | 142,823,016Source | 144,419,364Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 416,250Source | 416,250Source | 1,688,125Source | 1,753,792Source | 1,702,188Source | 1,338,542Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,580,753Source | 3,225,794Source | 1,643,000Source | 196,564Source | -987,554Source | 2,224,013Source | 6,091,413Source | 7,973,499Source | 5,752,771Source | 8,288,976Source |
| DepreciationUSD | — | — | — | — | — | — | 66,599Source | 60,912Source | 251,993Source | 249,623Source | 262,780Source | 258,707Source |
| General and Administrative ExpenseUSD | — | — | 2,570,375Source | 3,696,067Source | 2,365,993Source | 1,663,503Source | 1,137,343Source | 3,004,135Source | 9,602,351Source | 11,892,239Source | 13,335,364Source | 15,373,921Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 1,000Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 475,903Source | 479,252Source | 23Source | 470,618Source | 468,678Source | 483,529Source | 1,905,310Source | 1,926,241Source | — | — |
| Investment Income, InterestUSD | — | — | 788,694Source | 1,503,845Source | 400,257Source | 872,038Source | 562,977Source | 981,487Source | 3,323,855Source | 6,191,829Source | 7,323,008Source | 2,349,449Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | -100,000Source | 100,000Source | 100,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,688,341Source | -15,112,983Source | -5,450,273Source | -9,767,312Source | -3,452,619Source | -9,929,501Source | -33,846,661Source | -55,851,444Source | -37,542,510Source | -62,024,636Source |
| Nonoperating Income (Expense)USD | — | — | 312,791Source | 1,024,593Source | 400,234Source | 401,420Source | 94,299Source | 497,958Source | 1,418,545Source | 4,265,588Source | 5,251,573Source | 655,351Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 72,500Source | 67,800Source | 300,000Source | 300,000Source | 300,000Source | 200,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 71,140Source | 983,194Source | 1,103,940Source | 350,279Source | 194,129Source | 1,123,427Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -8,001,132Source | -16,137,576Source | -5,850,507Source | -10,168,732Source | -3,546,918Source | -10,427,459Source | -35,265,206Source | -60,117,032Source | -42,794,083Source | -62,679,987Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 1,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,688,341Source | -15,112,983Source | -5,450,273Source | -9,767,312Source | -3,452,619Source | -9,929,501Source | -33,846,661Source | -55,851,444Source | -37,542,510Source | -62,024,636Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.13Source | -0.25Source | -0.09Source | -0.16Source | -0.06Source | -0.17Source | -0.56Source | -0.94Source | -0.64Source | -1.06Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.13Source | -0.25Source | -0.09Source | -0.16Source | -0.06Source | -0.17Source | -0.56Source | -0.94Source | -0.64Source | -1.06Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 60,126,850Source | 59,530,113Source | 60,321,068Source | 60,045,530Source | 60,319,289Source | 59,887,277Source | 60,056,557Source | 59,484,794Source | 58,943,205Source | 58,405,897Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 60,126,850Source | 59,530,113Source | 60,321,068Source | 60,045,530Source | 60,319,289Source | 59,887,277Source | 60,056,557Source | 59,484,794Source | 58,943,205Source | 58,405,897Source |
| Interest Expense (non-operating)USD | — | — | 475,903Source | 479,252Source | 23Source | 470,618Source | 468,678Source | 483,529Source | 1,905,310Source | 1,926,241Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 2,570,375Source | 3,696,067Source | 2,365,993Source | 1,663,503Source | 1,137,343Source | 3,004,135Source | 9,602,351Source | 11,892,239Source | 13,335,364Source | 15,373,921Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | 33,846,661Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 33,846,661Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,071,435Source | 1,694,098Source |
| Investment Income, InterestUSD | — | — | 788,694Source | 1,503,845Source | 400,257Source | 872,038Source | 562,977Source | 981,487Source | 3,323,855Source | 6,191,829Source | 7,323,008Source | 2,349,449Source |
| Nonoperating Income (Expense)USD | — | — | 312,791Source | 1,024,593Source | 400,234Source | 401,420Source | 94,299Source | 497,958Source | 1,418,545Source | 4,265,588Source | 5,251,573Source | 655,351Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 72,500Source | 67,800Source | 300,000Source | 300,000Source | 300,000Source | 200,000Source |
| Research and Development ExpenseUSD | — | — | 5,430,757Source | 12,441,509Source | 3,484,514Source | 8,505,229Source | 2,409,575Source | 7,423,324Source | 25,662,855Source | 48,224,793Source | 29,458,719Source | 47,306,066Source |
Filing attachments
aldx-ex99_1.htm · 8-K · 2026-09-29
Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update CONFERENCE CALL September 29, 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operatio…
Read attachment ↗aldx-ex99_2.htm · 8-K · 2026-09-29
Exhibit 99.2 News Release Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease Concord, Mass. September 29, 2026 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDRR) for reprox…
Read attachment ↗aldx-ex99_1.htm · 8-K · 2026-06-10
EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors Lexington, Mass., June 9, 2026 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyra’s board of directors (the Board). “Ms. Deptula-Hicks brings decades of experience …
Read attachment ↗aldx-ex99_1.htm · 8-K · 2026-05-01
EX-99.1 2 aldx-ex99_1.htm EX-99.1 Innovative Therapeuticsfor Immune-Mediated Diseases CORPORATE OVERVIEW May 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of o…
Read attachment ↗aldx-ex99_1.htm · 8-K · 2026-03-17
EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease Lexington, Mass., March 17, 2026 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of…
Read attachment ↗aldx-ex99_1.htm · 8-K · 2025-12-16
EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease Lexington, Mass. December 15, 2025 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the…
Read attachment ↗